5-(3,5-dichloro-4-pyridylaminocarbonyl)-8-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 5-(3,5-dichloro-4-pyridylaminocarbonyl)-8-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran
• 英文别名: 5-(3,5-dichloro-pyridin-4-ylaminocarbonyl)-8-methoxy-2,2-dimethyl-3,4-dihydrobenzopyran；N-(3,5-dichloropyridin-4-yl)-8-methoxy-2,2-dimethyl-3,4-dihydrochromene-5-carboxamide
• 化学式: C₁₈H₁₈Cl₂N₂O₃
• 分子量: 381.259
• InChiKey: QSVYCCGWISVICA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE
  申请人：——

  公开号：US20020128290A1

  公开（公告）日：2002-09-12

  An oxygen-containing heterocyclic compound represented by following Formula (I): 1 wherein R 1 and R 2 independently represent hydrogen, lower alkyl, cyano, —(CH 2 ) n —E 1 —CO—G 1 (wherein E 1 represents a bond, O, or NH; and G 1 represents hydrogen, substituted or unsubstituted lower alkyl, OR 6 , or NR 7 R 8 ; and n represents an integer of 0 to 4), or the like; R 1 and R 2 are combined to represent a saturated carbon ring together with a carbon atom adjacent thereto; or R 2 , and R 11 or R 13 described below are combined to form a single bond; R 3 represents hydrogen, phenyl, or halogen; R 4 represents hydroxy, lower alkoxy, or the like; A represents —C(R 9 )(R 10 )— or O; B represents O, NR 11 , —C(R 12 )(R 13 )—, or —C(R 14 )(R 15 )—C(R 16 )(R 17 )—; D represents (i) —C(R 18 )(R 19 )—X— (wherein X represents —C(R 21 )(R 22 )—, S, or NR 23 ), (ii) —C(R 19a )═Y— [Y represents —C(R 24 )—Z— (wherein Z represents CONH, CONHCH 2 , or a bond), or N], or (iii) a bond; and R 5 represents aryl, an aromatic heterocyclic group, cycloalkyl, pyridine-N-oxide, cyano, or lower alkoxycarbonyl; or pharmaceutically acceptable salts thereof.

  以下是由下式（I）表示的含氧杂环化合物： 其中R1和R2独立地表示氢、较低的烷基、氰基、—（CH2）n—E1—CO—G1（其中E1表示键、O或NH；G1表示氢、取代或未取代的较低烷基、OR6或NR7R8；n表示0到4的整数），或类似物；R1和R2结合表示与相邻碳原子一起形成饱和碳环；或R2，以及下文描述的R11或R13结合形成单键；R3表示氢、苯基或卤素；R4表示羟基、较低的烷氧基或类似物；A表示—C（R9）（R10）—或O；B表示O、NR11、—C（R12）（R13）—或—C（R14）（R15）—C（R16）（R17）—；D表示（i）—C（R18）（R19）—X—（其中X表示—C（R21）（R22）—、S或NR23）、（ii）—C（R19a）═Y—［Y表示—C（R24）—Z—（其中Z表示CONH、CONHCH2或键），或N］，或（iii）键；R5表示芳基、芳香杂环基、环烷基、吡啶-N-氧化物、氰基或较低烷氧羰基；或其药学上可接受的盐。
• Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor
  申请人：——

  公开号：US20040087653A1

  公开（公告）日：2004-05-06

  Therapeutic methods for the prevention and treatment of respiratory diseases or conditions are described, the methods including administering to a subject in need thereof a respiratory disease or condition effective amount of a selective inhibitor of inducible nitric oxide synthase.

  本文描述了用于预防和治疗呼吸系统疾病或症状的治疗方法，其中的方法包括向需要治疗的对象施用诱导型一氧化氮合酶选择性抑制剂的有效剂量。
• OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP0771794A1

  公开（公告）日：1997-05-07

  An oxygen-containing heterocyclic compound represented by following Formula (I): wherein R1 and R2 independently represent hydrogen, lower alkyl, cyano, -(CH2)n-E-CO-F (wherein E represents a bond, O, or NH; F represents OR6 or NR7R8; and n represents an integer of 0 to 4), or the like; R1 and R2 are combined to represent a saturated carbon ring together with a carbon atom adjacent thereto; or R2, and R11 or R13 described below are combined to form a single bond; R3 represents hydrogen, phenyl, or halogen; R4 represents hydroxy, lower alkoxy, or the like; A represents -C(R9)(R10)- or O; B represents O, NR11, -C(R12)(R13)-, or -C(R14)(R15)-C(R16)(R17)-; D represents (i) -C(R18)(R19)-X- (wherein X represents -C(R21)(R22)-, S, or NR23), (ii) -C(R19a)=Y- [Y represents -C(R24)-Z- (wherein Z represents CONH, CONHCH2, or a bond), or N], or (iii) a bond; and R5 represents aryl, an aromatic heterocyclic group, cycloalkyl, pyridine-N-oxide, cyano, or lower alkoxycarbonyl; or a pharmaceutically acceptable salt thereof.

  由下式（I）代表的含氧杂环化合物： 其中 R1 和 R2 独立地代表氢、低级烷基、氰基、-(CH2)n-E-CO-F（其中 E 代表键、O 或 NH；F 代表 OR6 或 NR7R8；n 代表 0 至 4 的整数）或类似物；R1 和 R2 结合在一起代表一个饱和碳环及其邻近的碳原子；或 R2 和下述 R11 或 R13 结合在一起形成单键；R3 代表氢、苯基或卤素；R4 代表羟基、低级烷氧基或类似物；A 代表-C(R9)(R10)-或 O；B 代表 O、NR11、-C(R12)(R13)-或-C(R14)(R15)-C(R16)(R17)-；D 代表 (i) -C(R18)(R19)-X- （其中 X 代表 -C(R21)(R22)-、S 或 NR23），(ii) -C(R19a)=Y- [Y 代表 -C(R24)-Z- （其中 Z 代表 CONH、CONHCH2 或键）或 N]，或 (iii) 键；R5 代表芳基、芳香杂环基团、环烷基、吡啶-N-氧化物、氰基或低级烷氧羰基；或其药学上可接受的盐。
• Combination of a pde iv inhibitor and a tnf-alpha antagonist
  申请人：Warner M James

  公开号：US20060083714A1

  公开（公告）日：2006-04-20

  The subject invention relates to therapeutic combinations and methods for the treatment of inflammatory conditions and diseases. Particularly the present invention relates to treatments and methods for PDE IV-related conditions and for TNF-alpha-related conditions using a combination of a PDE IV inhibitor and a TNF-alpha antagonist.

  本发明涉及治疗炎症和疾病的治疗组合和方法。特别是本发明涉及使用 PDE IV 抑制剂和 TNF-α 拮抗剂组合治疗 PDE IV 相关疾病和 TNF-α 相关疾病的治疗方法。
• A SELECTIVE INOS INHIBITOR AND A PDE INHIBITOR IN COMBINATION FOR THE TREATMENT OF RESPIRATORY DISEASES
  申请人：Pharmacia Corporation

  公开号：EP1505972A2

  公开（公告）日：2005-02-16